Cagrilintide Dosage Chart & Schedule
A long-acting synthetic analog of the hormone amylin, developed for weight management and most often studied alongside semaglutide in the fixed combination known as CagriSema. It remains investigational.
In obesity research, cagrilintide is an investigational once-weekly amylin analog given subcutaneously and titrated slowly from roughly 0.3 mg up toward 2.4 mg. It is most often studied alongside semaglutide in the fixed combination CagriSema, and it is not approved as a standalone product.
Figures describe how Cagrilintide is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once weekly
- Weekly total
- 0.3 mg
- Cycle
- About 4 weeks, then step up
Trials began low and increased the dose every few weeks.
- Frequency
- Once weekly
- Weekly total
- 1.2 mg
- Cycle
- About 4 weeks, then step up
One of the intermediate steps used before reaching the target dose.
- Frequency
- Once weekly
- Weekly total
- 2.4 mg
- Cycle
- Ongoing in trials
In CagriSema this 2.4 mg is paired 1:1 with 2.4 mg semaglutide.
Studied with semaglutide (CagriSema)
- Most trial data pair cagrilintide 1:1 with semaglutide (2.4 mg + 2.4 mg once weekly).
- As an amylin analog, its satiety and gastric-emptying effects are proposed to complement the GLP-1 pathway.
Investigational
- Not approved as a standalone product; the doses above come from obesity trials, not a human-use recommendation.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the maintenance (trial target) protocol (Once weekly).
Dosing day Off
Cagrilintide reconstitution
5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe (~96 units for 2.4 mg).
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- Reconstitute the lyophilized powder with bacteriostatic water (about 2 mL for a 5 mg vial gives 2,500 mcg/mL) and swirl gently rather than shaking.
- Draw once-weekly doses on a U-100 insulin syringe; at 2,500 mcg/mL a 2.4 mg dose is just under 1 mL.
- Refrigerate the reconstituted vial, keep it out of light, and rotate subcutaneous sites such as abdomen and thigh.
Cagrilintide dosing FAQ
How often is cagrilintide dosed in research?
As a long-acting amylin analog, trials use once-weekly subcutaneous injections, mirroring its roughly week-long pharmacokinetics.
Why start at 0.3 mg instead of the target dose?
Obesity trials titrated slowly from about 0.3 mg toward 2.4 mg over several weeks to limit gastrointestinal effects such as nausea, a common feature of the incretin and amylin classes.
What is the highest dose studied?
Weekly subcutaneous doses were escalated up to roughly 2.4 mg in obesity trials; that is the target maintenance dose referenced above.
How does dosing differ in CagriSema?
In the CagriSema combination, cagrilintide is paired one-to-one with semaglutide, commonly cited as 2.4 mg + 2.4 mg once weekly.
Sources
Categories: GLP-1 & Metabolic · Status: Approved (see notes). This page is educational and for laboratory research use only; it is not medical advice.